Vertex Unveils First Patient Results On Potential Diabetes Treatment

  • Vertex Pharmaceuticals Incorporated VRTX has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D). 
  • VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy.
  • The patient, who had suffered five potentially life-threatening hypoglycemic (low blood sugar) episodes in the year before the therapy, was injected with synthetic insulin-producing cells. 
  • After 90 days, the patient’s new cells produced insulin steadily and ramped up their insulin production.
  • The patient’s HbA1c, a metric for blood sugar levels, dropped from an average of 8.4% to 7.2%. 
  • Most notably, the patient needed just three units of insulin per day compared to 34 units before treatment, a 91% reduction.
  • There were no serious adverse events considered related to VX-880, and most of the adverse events were considered mild to moderate.
  • Vertex is also progressing IND-enabling studies for its encapsulated islet cell program and plans to file an IND in 2022.
  • Related: Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies.
  • Price Action: VRTX shares closed lower 0.53% at $180.80 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 1 TrialPhase 2 TrialType I Diabetes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!